Background: NEPA, an oral fixed combination of the NK 1 RA netupitant (300 mg) and clinically/pharmacologically distinct 5-HT 3 RA palonosetron (PALO, 0.50 mg), is the first fixed antiemetic combination to have been approved. A single oral NEPA capsule plus dexamethasone (DEX) given before anthracycline-cyclophosphamide (AC) and non-AC highly emetogenic chemotherapy (HEC) showed superior prevention of chemotherapy-induced nausea and vomiting (CINV) over PALO plus DEX for 5 days postchemotherapy. The safety of NEPA was well-established in the phase II/III clinical program in 1169 NEPA-treated patients. An intravenous (i.v.) formulation of the NEPA combination (fosnetupitant 235 mg plus PALO 0.25 mg) has been developed.
Introduction
The development of new antiemetics has substantially changed the landscape for prevention of chemotherapy-induced nausea and vomiting (CINV). The current antiemetic armamentarium now allows for prevention of emesis in most cancer patients receiving emetogenic chemotherapy, while improvements in prevention of nausea are less pronounced, particularly during the delayed phase following chemotherapy.
With an improved understanding of CINV neuropharmacology and the development of new agents targeting different receptors involved in the CINV process, multi-agent antiemetic prophylactic combinations are recommended for the highly emetogenic chemotherapy (HEC) setting. Unfortunately, adherence to antiemetic guideline recommendations is suboptimal [1, 2] , potentially in part due to the perceived complexity of these antiemetic combinations. A recently published survey of United States (US)-based oncology nurses not only revealed inconsistencies between antiemetic practice patterns and antiemetic guideline recommendations, but also revealed a discrepancy between nurses' reports of high proportions of patients with inadequate CINV control despite their belief in adequate guidelines adherence [3] .
Multiple classes of antiemetics are available in different formulations [e.g. oral, intravenous (i.v.), transdermal], offering options for healthcare providers and patients in various settings. Providing alternate drug formulations can help address unmet needs of patients and prescribers by promoting greater patient adherence to prescribed treatment regimens.
NEPA is the first and only fixed antiemetic combination agent and is comprised of netupitant, a highly selective NK 1 receptor antagonist (RA) and palonosetron (PALO), an established pharmacologically distinct 5-HT 3 RA [4, 5] . Approval of oral NEPA (netupitant 300 mg/PALO 0.50 mg) in the US and Europe was based on studies demonstrating that a single oral NEPA capsule plus dexamethasone (DEX) given before cisplatin-and anthracycline-cyclophosphamide (AC)-based chemotherapy demonstrated superior efficacy in preventing CINV over PALO plus DEX for 5 days postchemotherapy [6] [7] [8] . The safety of oral NEPA was also well-established in the phase II/III clinical program in 1169 NEPA-treated patients in single or repeated cycles [9] .
To offer additional convenience for patients and healthcare providers, a fixed i.v. combination formulation of NEPA was developed using a water-soluble phosphorylated pro-drug of netupitant called fosnetupitant. Intravenous fosnetupitant chloride at dosages from 20 to 390 mg has been administered to 180 healthy volunteers in prior studies, with a good safety profile [10] . The selected bioequivalent dose of fosnetupitant for the i.v. formulation is 235 mg (corresponding to 260 mg of fosnetupitant chloride) [10] . The selected i.v. dose for PALO is 0.25 mg, the same registered dose of i.v. Aloxi V R . Fosnetupitant does not require any surfactant, emulsifier or solubility enhancer to get a clear injectable solution. The formulation of i.v. NEPA has been simplified reducing the number of excipients and associated toxicities [11] .
Given the demonstrated bioequivalence of 235 mg i.v. fosnetupitant and the netupitant component of oral NEPA (300 mg netupitant þ 0.25 mg PALO) in terms of netupitant area under the curve, a phase III study was designed with the primary objective to assess the overall safety and tolerability of a single dose of i.v. NEPA administered with DEX over initial and repeated cycles of HEC.
Patients and methods

Study design
This was a phase III, multinational, multicenter, randomized, doubleblind, double-dummy, parallel-group multiple-cycle safety study [NCT02517021] At study entry, patients were required to have an Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2. Patients were not eligible to enter the study or continue in repeated cycles if scheduled to receive: (i) moderately emetogenic chemotherapy or HEC beyond day 1 (i.e. multiday chemotherapy), (ii) moderately or highly emetogenic radiotherapy within 1 week before day 1 or between days 1 and 5, or (iii) a bone marrow or stem-cell transplant. Patients were not allowed to receive any drug with potential antiemetic efficacy within 24 h before the start of reference chemotherapy on day 1 and were excluded if they experienced any vomiting, retching or mild nausea within 24 h before reference chemotherapy administration. Patients were excluded from entering the study if they had a history or predisposition to cardiac conduction abnormalities, except for incomplete right bundle branch block. They were also ineligible if they had a history of, or risk factors for Torsade de Pointes, or any severe cardiovascular diseases within 3 months before day 1 of the first cycle, including myocardial infarction, unstable angina pectoris, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic congestive heart failure New York Heart Association class III and IV, or severe uncontrolled arterial hypertension.
Treatment
At cycle 1, patients were randomly assigned (stratified by sex and country) to receive either i.v. NEPA or oral NEPA, both with 12 mg DEX, before reference chemotherapy on day 1. i.v. NEPA was administered as a 30-min infusion of 50 ml solution and initiated 30 min before chemotherapy, while oral NEPA was taken as an oral capsule 60 min before chemotherapy. Blinding was ensured by administration of matching placebos. Oral DEX was open-label and administered 30 min before chemotherapy immediately before initiating the infusion of i.v. NEPA/placebo; subsequently, daily DEX doses (8 mg/day) were taken in the morning of days 2-4. A previous pharmacokinetic study confirmed that administration of fosnetupitant resulted in a similar increase in DEX exposure as that seen with netupitant [10] ; therefore, the DEX doses were those recommended in the oral NEPA package insert. For subsequent cycles, patients received the same treatment they were randomized to in cycle 1.
Rescue medication was permitted on an as-needed basis to alleviate established, refractory, or persistent nausea or vomiting. The investigator was provided with metoclopramide tablets to be distributed to patients as needed; however, he/she was authorized to use an alternative rescue medication if needed, based on his/her clinical judgment.
Assessments
The primary safety assessment was evaluation of treatment-emergent adverse events (TEAEs, i.e. those occurring after the first dose of study treatment) with secondary assessments of vital signs, physical examination, clinical laboratory tests, and electrocardiograms (ECGs). The causal relationship between AEs and study treatments was assessed by the investigators, with AEs considered treatment-related if unassessable or missing or if deemed possibly, probably, or definitely related to study drug.
During each cycle, ECGs were recorded predose, at the end of infusion (before starting chemotherapy), and 5, 24, and 120 h postdose. Recommended criteria used to interpret ECG outlier results suggest that a potential safety signal would be a change in QT interval corrected by Fridericia (QTcF) from below 500 ms at baseline (predose) to above 500 ms in more than 5% of patients or a change from baseline of more than 60 ms in more than 15% of patients [12] .
For the secondary assessment of efficacy, each patient completed a diary from the start of chemotherapy on day 1 for 5 days (0-120 h) of each cycle, capturing emetic episodes and rescue medications intake.
Statistical analysis
The primary aim of this study was to characterize the safety and tolerability of a single dose of i.v. NEPA. Although no formal comparisons between treatment groups were planned, the addition of the oral NEPA control group was intended to help interpret any unexpected safety finding in the i.v. NEPA group. Four hundred patients were to be randomized 1 : 1 to either i.v. or oral NEPA. It was expected that with 200 patients in each group, 100 patients would be treated for 4 cycles with i.v. NEPA and therefore, if a given adverse event was not observed, an adverse event incidence of 3% could be excluded with 95% confidence. Adverse events were listed and summarized by frequency tables.
ECG data were summarized including changes from baseline for quantitative variables and frequencies of treatment-emergent abnormalities. Descriptive statistics were presented by treatment of QTcF. An outlier analysis depicting the number and proportion of patients who met specific predefined criteria (with reference to ICH E14) was carried out. The number of patients who had treatment-emergent abnormalities in ECG results was summarized in frequency tables.
For efficacy end points during cycle 1, percentages [including 95% confidence interval (CI) using the Wilson score method] of patients with complete response (CR: no emesis and no rescue use) and no emetic episodes were summarized by treatment for the overall (0-120 h) phase. Differences between groups in response rate and 95% CI for the difference were presented using Newcombe-Wilson's method and also the stratum-adjusted Cochran-Mantel-Haenszel method for the risk difference. Sex and country were used as strata. Results were interpreted only in a descriptive manner.
The safety population consisted of all patients who received at least one dose of study drug (including partial infusion); patients were assigned to the treatment group based on actual treatment received. This population was used for all safety analyses.
The full analysis set included all patients who were randomized, received study drug and HEC; patients were assigned to the treatment group based on their randomized treatment. This population was used for efficacy analyses.
Results
A total of 404 patients (203 i.v. NEPA, 201 oral NEPA) were included in the safety population for a total of 1312 exposures in the entire study (supplementary Figure S1 , available at Annals of Oncology online); 91% of patients completed cycle 1 and 59% completed cycle 4.
Baseline characteristics were similar in the two treatment groups (Table 1 ) and were consistent across cycles. Most patients were male and white; lung cancer was the most common cancer type with almost all patients receiving cisplatin-based chemotherapy.
Safety
There were a total of 667 infusions of i.v. NEPA administered during the study and 645 capsules of oral NEPA taken. The mean number of doses per patient was 3.3 and 3.2 for i.v. NEPA and oral NEPA, respectively; the median was 4 doses (equivalent to 4 cycles/patient) in both groups.
The overall incidence and intensity of TEAEs were similar between the two treatment groups in cycle 1 and throughout the study ( Table 2 ). The majority of patients experienced TEAEs of mild/moderate severity, with 25% of patients in both groups experiencing severe TEAEs during cycle 1. The overall incidence of TEAEs decreased over repeated cycles in both groups (cycles 1-4 i.v. NEPA: 59.1%, 53.1%, 52.1%, 26.2%; oral NEPA: 67.2%, 52.5%, 49.3%, 24.8%). There were no serious treatment-related AEs (TRAEs) and no study-drug-related TEAEs leading to death during the study (Table 2 ). Two i.v. NEPA patients experienced TRAEs leading to discontinuation; one due to increase in hepatic enzymes in cycle 1, and one disease progression in cycle 2; the relationship of this progression to i.v. NEPA was unassessable and therefore deemed treatment related. One oral NEPA patient experienced a grade 2 TRAE of hypersensitivity; the patient recovered within 10 min of onset leading to discontinuation in cycle 2.
The most frequently reported TEAEs of any grade (i.e. those reported by 5% of patients in either treatment group) were consistent with those expected for cancer patients undergoing predominantly cisplatin-based chemotherapy; similar incidence rates were seen for i.v. NEPA and oral NEPA ( Table 3 ). The incidence of common TEAEs for the 5-HT 3 RA and NK 1 RA classes were similar in both groups including constipation (10.3% and 10.9%), headache (5.4% and 4.5%), and diarrhea (3.9% and 5.0%) for i.v. and oral NEPA, respectively. The most frequently reported grade 3 and 4 TEAEs with an incidence of 2% of patients in either treatment group are also summarized in Table  3 . Overall, grade 3 TEAEs were experienced by 61 (30.0%) patients in the i.v. NEPA group and 54 (26.9%) patients in the oral NEPA group, while grade 4 TEAEs were experienced by 15 (7.4%) and 22 (10.9%) of patients in the i.v. NEPA and oral NEPA groups, respectively. Neutropenia was the most frequent grade 3/4 TEAE reported during this study.
The most common TRAEs during the entire study were constipation (6.4% i.v. NEPA, 6.0% oral NEPA) and increased alanine aminotransferase (2.0% both groups); all other TRAEs occurred in <2% of patients.
The frequency of TEAEs pertaining to local tolerability of infusion (of i.v. NEPA or placebo in the oral NEPA group) was very low (supplementary Table S1 , available at Annals of Oncology online). None of these infusion site reactions were considered by the Investigator to be related to the infusion of i.v. (or oral) NEPA.
Cardiac safety
Changes from baseline in 12-lead ECGs after treatment were similar between groups. In cycle 1, the mean changes from baseline in QTcF were small and similar between groups with the greatest increase at 5 h postdose (8.2 ms for both i.v. and oral NEPA) and a slight decrease from baseline at 120 h. Similar results were observed during consecutive cycles 2-4 for both groups. Across all cycles, no patient had a QTcF >500 ms with a baseline value of 500 ms. One patient (0.5%) had a >60 ms change from baseline in QTcF interval at 24 h after treatment with i.v. NEPA, and 1 patient (0.5%) had a change from baseline of >60 ms at the end of infusion, 5, 24, and 120 h after oral NEPA.
The most frequently reported treatment-emergent ECG abnormalities throughout the study were atrial premature complexes (25.1% and 18.9%), sinus tachycardia (18.2% and 19.4%), and flat ST segment, T-wave, and U-wave (21.7% and 16.9%) in the i.v. NEPA and oral NEPA group, respectively. Atrial fibrillation occurred in 3 patients [2 (1.0%) i.v. NEPA and 1 (0.5%) oral NEPA]; atrial flutter occurred in 1 (0.5%) i.v. NEPA patient.
Efficacy
Complete response rates in the overall phase for cycle 1 were 76.8% for i.v. NEPA and 84.1% for oral NEPA (supplementary Figure S2 , available at Annals of Oncology online). No emesis rates were similar (84.2% i.v. NEPA and 88.6% oral NEPA).
Discussion
Consistent with the regulatory strategy for several approved i.v. NK 1 RAs [13, 14] , a bioequivalence approach was pursued for the development of the i.v. formulation of NEPA [10] . However, the development program has also included the current repeated dose safety study in patients undergoing non-AC HEC to further establish the safety of the i.v. formulation and potentially uncover adverse drug reactions [15] that may appear during subsequent clinical practice. An additional similar phase IIIb study is underway evaluating the safety of i.v. NEPA in patients receiving ACbased chemotherapy.
This study showed that the i.v. formulation of NEPA was safe and well-tolerated in patients with solid tumors receiving HEC-based chemotherapy. Intravenous NEPA had a similar safety profile to that observed with oral NEPA. The adverse event profile of the i.v. formulation was consistent with that of oral NEPA based on the phase II/III program where more than 3200 patients received over 9300 treatment cycles of either oral NEPA, PALO, or aprepitant-regimen comparators [9] . The safety profile for i.v. NEPA and oral NEPA was also consistent with that expected for these drug classes and for patients with a variety of cancer types receiving chemotherapy. The incidence of TRAEs was similar and relatively low in both groups (8.9% and 9.5% for i.v. NEPA and oral NEPA, respectively, during cycle 1 and 12.8% and 11.4% during the entire study). Constipation and increased alanine aminotransferase were the only two TRAEs exceeding 2% throughout the study. The majority of patients experienced TEAEs of mild/moderate intensity with only a few patients experiencing severe TRAEs. Moreover, there were no serious TRAEs or TRAEs leading to death in either treatment group. There was no indication of increasing adverse events, whether treatment-related or not, over multiple cycles.
Infusion site reactions have been reported for fosaprepitant [13] and i.v. rolapitant [14] and the product labeling for both includes precaution/warning statements regarding the potential for hypersensitivity reactions/anaphylaxis [13] [14] [15] ; in addition, marketed distribution of i.v. rolapitant was recently suspended as a result of anaphylaxis/anaphylactic shock and hypersensitivity reactions reported in the postmarketing setting. In light of this, it noteworthy that there were no injection site reactions considered to be related to i.v. NEPA over repeated cycles and no instance of anaphylaxis with either formulation of NEPA. Only one instance of hypersensitivity was reported (0.5%) for a patient receiving oral NEPA. The low incidence of these events may be attributable to the chemical characteristics of fosnetupitant and to a reduced number of excipients present in the i.v. NEPA formulation.
Consistent with prior oral NEPA trials, there were no cardiac safety concerns based on ECGs observed with either i.v. or oral NEPA formulations during initial or repeated cycles.
There are inherent limitations in studies designed for registration purposes; this study was not designed nor powered for an efficacy comparison of i.v. NEPA and oral NEPA. However, both i.v. and oral NEPA showed high responses in preventing CINV, with overall complete response and no emesis rates during cycle 1 exceeding 76%. Reassuringly, the overall complete response rate for i.v. NEPA (77%) parallels results from prior HEC trials for other NK 1 RA-containing regimens (e.g. aprepitant 72% [16] , oral rolapitant 70% [17] , and 68% [17] ).
Intravenous NEPA is a safe, effective, convenient, and simple single-dose prophylactic antiemetic targeting two distinct CINV pathways as recommended by treatment guidelines for HEC. Grade based on Common Terminology Criteria for Adverse Events (CTCAE V.4.03). TEAE: any treatment-emergent adverse event (i.e. reported after first study treatment intake).
